A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

• Status: Unknown status
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparison of two combination chemotherapies in the treatment of patients with SLCL

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Collaborators: Aventis Pharmaceuticals; Pfizer
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Irinotecan

Criteria

Inclusion Criteria:

• cytological or histological proven SCLC Stage I or II at 1st diagnosis

• no prior chemotherapy

• measurable tumor disease

• karnofsky performance 70

Exclusion Criteria:

• second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)

• NYHA III

• chronic diarrhea, obstructive bowel syndrome